CO2019002889A2 - Tratamientos de combinación que comprenden la administración de imidazopirazinonas - Google Patents
Tratamientos de combinación que comprenden la administración de imidazopirazinonasInfo
- Publication number
- CO2019002889A2 CO2019002889A2 CONC2019/0002889A CO2019002889A CO2019002889A2 CO 2019002889 A2 CO2019002889 A2 CO 2019002889A2 CO 2019002889 A CO2019002889 A CO 2019002889A CO 2019002889 A2 CO2019002889 A2 CO 2019002889A2
- Authority
- CO
- Colombia
- Prior art keywords
- administration
- disease
- treatment
- combination treatments
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Resumen La presente invención proporciona tratamientos de combinación que comprenden la administración de compuestos que son inhibidores de la enzima PDE1 y de otros compuestos útiles en el tratamiento de trastornos neurodegenerativos tales como la Enfermedad de Alzheimer, la Enfermedad de Parkinson o la Enfermedad de Huntington. Aspectos separados de la invención están dirigidos al uso combinado de dichos compuestos para el tratamiento de trastornos neurodegenerativos y/o cognitivos. La presente invención también proporciona composiciones farmacéuticas que comprenden dichos inhibidores de la enzima PDE1 junto con otros compuestos útiles en el tratamiento de trastornos neurodegenerativos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201600660 | 2016-10-28 | ||
PCT/EP2017/077503 WO2018078042A1 (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising administration of imidazopyrazinones |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019002889A2 true CO2019002889A2 (es) | 2019-06-19 |
Family
ID=60302087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0002889A CO2019002889A2 (es) | 2016-10-28 | 2019-03-27 | Tratamientos de combinación que comprenden la administración de imidazopirazinonas |
Country Status (18)
Country | Link |
---|---|
US (1) | US10912773B2 (es) |
EP (1) | EP3532053A1 (es) |
JP (1) | JP2020500841A (es) |
KR (1) | KR20190077349A (es) |
CN (1) | CN109803653A (es) |
AR (1) | AR109990A1 (es) |
AU (1) | AU2017350477A1 (es) |
BR (1) | BR112018013084A2 (es) |
CA (1) | CA3041595A1 (es) |
CL (1) | CL2019001092A1 (es) |
CO (1) | CO2019002889A2 (es) |
IL (1) | IL265633B (es) |
MA (1) | MA46621A (es) |
MX (1) | MX2019004859A (es) |
RU (1) | RU2019108717A (es) |
SG (1) | SG11201903061YA (es) |
WO (1) | WO2018078042A1 (es) |
ZA (1) | ZA201902090B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之***並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
CA3041607A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
WO2019151274A1 (ja) | 2018-02-01 | 2019-08-08 | 日本たばこ産業株式会社 | 含窒素複素環アミド化合物及びその医薬用途 |
GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
WO2024042480A1 (en) | 2022-08-26 | 2024-02-29 | Suven Life Sciences Limited | Heteroaromatic compounds for the treatment of neurological disorders |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
WO2004099211A1 (de) | 2003-05-09 | 2004-11-18 | Bayer Healthcare Ag | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
EP1828192B1 (en) * | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2007025103A2 (en) | 2005-08-23 | 2007-03-01 | Intra-Cellular Therapies, Inc. | Organic compounds for treating reduced dopamine receptor signalling activity |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
GEP20125405B (en) | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
JP2011504892A (ja) | 2007-11-30 | 2011-02-17 | ビオティエ セラピーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホスホジエステラーゼ10の阻害剤としてのアリール及びヘテロアリール縮合イミダゾ(1,5−a)ピラジン |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
CA2736304A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
CN102227167A (zh) | 2008-12-06 | 2011-10-26 | 细胞内治疗公司 | 有机化合物 |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
JP5917394B2 (ja) | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | 病理学的タウタンパク質の免疫学的標的化方法 |
US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
AU2011289629B2 (en) | 2010-08-12 | 2014-07-03 | Eli Lilly And Company | Anti-N3pGlu amyloid beta peptide antibodies and uses thereof |
EP3181566A1 (en) | 2010-09-20 | 2017-06-21 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP3121178B1 (en) * | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor |
WO2013110768A1 (en) | 2012-01-26 | 2013-08-01 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
BR112014031731B1 (pt) | 2012-06-18 | 2022-12-06 | Dart Neuroscience (Cayman) Ltd | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos |
CN105377846B (zh) | 2013-03-15 | 2018-03-20 | 细胞内治疗公司 | 有机化合物 |
JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
MX2016010777A (es) | 2014-02-19 | 2016-10-26 | H Lundbeck As | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer. |
JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
US20170273985A1 (en) | 2014-09-18 | 2017-09-28 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之***並吡酮 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
US20180044343A1 (en) | 2015-03-16 | 2018-02-15 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
BR112017007472A2 (pt) | 2015-08-12 | 2018-01-23 | H Lundbeck As | 2-amino-3-fluoro-3-(fluoro metil)-6-metil-6-fenil- 3,4,5,6-tetra-hidropiridinas como inibidores de bace1 |
TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
MX2018014612A (es) * | 2016-06-23 | 2019-03-01 | Avent Inc | Miembro de bobina ecogenico para un ensamble de cateter. |
JP2018076285A (ja) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体を含む医薬 |
ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
CA3041607A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
-
2017
- 2017-10-26 MX MX2019004859A patent/MX2019004859A/es unknown
- 2017-10-26 US US16/345,157 patent/US10912773B2/en active Active
- 2017-10-26 CN CN201780063188.6A patent/CN109803653A/zh active Pending
- 2017-10-26 BR BR112018013084A patent/BR112018013084A2/pt not_active IP Right Cessation
- 2017-10-26 EP EP17797276.7A patent/EP3532053A1/en not_active Withdrawn
- 2017-10-26 JP JP2019522586A patent/JP2020500841A/ja active Pending
- 2017-10-26 WO PCT/EP2017/077503 patent/WO2018078042A1/en unknown
- 2017-10-26 AU AU2017350477A patent/AU2017350477A1/en not_active Abandoned
- 2017-10-26 KR KR1020197011560A patent/KR20190077349A/ko not_active Application Discontinuation
- 2017-10-26 CA CA3041595A patent/CA3041595A1/en not_active Abandoned
- 2017-10-26 RU RU2019108717A patent/RU2019108717A/ru not_active Application Discontinuation
- 2017-10-26 MA MA046621A patent/MA46621A/fr unknown
- 2017-10-26 SG SG11201903061YA patent/SG11201903061YA/en unknown
- 2017-10-27 AR ARP170102996A patent/AR109990A1/es unknown
-
2019
- 2019-03-26 IL IL265633A patent/IL265633B/en active IP Right Grant
- 2019-03-27 CO CONC2019/0002889A patent/CO2019002889A2/es unknown
- 2019-04-03 ZA ZA2019/02090A patent/ZA201902090B/en unknown
- 2019-04-22 CL CL2019001092A patent/CL2019001092A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US10912773B2 (en) | 2021-02-09 |
IL265633B (en) | 2021-05-31 |
CL2019001092A1 (es) | 2019-07-05 |
CN109803653A (zh) | 2019-05-24 |
US20190282572A1 (en) | 2019-09-19 |
RU2019108717A (ru) | 2020-11-30 |
KR20190077349A (ko) | 2019-07-03 |
MA46621A (fr) | 2021-06-02 |
AU2017350477A1 (en) | 2019-04-18 |
IL265633A (en) | 2019-05-30 |
WO2018078042A1 (en) | 2018-05-03 |
CA3041595A1 (en) | 2018-05-03 |
BR112018013084A2 (pt) | 2018-12-11 |
RU2019108717A3 (es) | 2021-01-29 |
SG11201903061YA (en) | 2019-05-30 |
ZA201902090B (en) | 2020-10-28 |
MX2019004859A (es) | 2019-06-20 |
AR109990A1 (es) | 2019-02-13 |
EP3532053A1 (en) | 2019-09-04 |
JP2020500841A (ja) | 2020-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019002889A2 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
CL2017003073A1 (es) | Inhibidores de tirosina-cinasas | |
SV2018005787A (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
ECSP17028463A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 | |
CO2018009889A2 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
DOP2016000195A (es) | Compuestos | |
CL2019001091A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas. | |
MX2019007587A (es) | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. | |
CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
GT201300209A (es) | Compuestos y composiciones como inhibidores de la trk | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
BR112015022545A2 (pt) | compostos de pirazolo e os usos disso | |
CL2012001955A1 (es) | Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras. | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
CR20160394A (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
CL2019001891A1 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas. | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
BR112015001096A2 (pt) | derivados de di e tri-heteroaril como inibidores de agregação de proteína | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto |